Physician profile
Jonathan D Marmur
NPI 1184619652
$4,149.43
in general payments reported to CMS, 2019-2025
21 companies · $607 in 2025
The $607 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,325 · 2020: $364 · 2021: $412 · 2022: $787 · 2023: $466 · 2024: $189 · 2025: $607.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,162 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,162.25 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,257.78 | 2019-2023 | Dragonfly Opstar, Xience Skypoint |
| Edwards Lifesciences Corporation | $484.07 | 2019 | |
| Boston Scientific Corporation | $224.27 | 2019-2025 | Rotapro, Avvigo Guidance System |
| Kestra Medical Technology Services, INC. | $210.57 | 2024-2025 | Assure Wcd |
| Abiomed | $197.12 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $159.82 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $124.35 | 2025 | Opsumit, Uptravi |
| Nuwellis, INC. | $121.99 | 2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $54.08 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $52.64 | 2020-2025 | Farxiga |
| Philips North America LLC | $42.09 | 2019 | |
| Impulse Dynamics (USA) INC. | $39.48 | 2025 | Optimizer |
| Alnylam Pharmaceuticals INC. | $36.01 | 2025 | Amvuttra |
| Pfizer INC. | $26.96 | 2025 | |
| Novartis Pharmaceuticals Corporation | $24.40 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $21.15 | 2021 | |
| Medtronic, INC. | $20.42 | 2023 | Corevalve Evolut R |
| Shockwave Medical, INC | $17.74 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Astellas Pharma US INC | $14.41 | 2020 | |
| Medtronic Vascular, INC. | $14.07 | 2019 | |
| Z-Medica, LLC | $6.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Marmur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.